{"protocolSection": {"identificationModule": {"nctId": "NCT02814643", "orgStudyIdInfo": {"id": "D3250C00033"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma", "officialTitle": "A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.", "acronym": "ALIZE"}, "statusModule": {"statusVerifiedDate": "2018-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-07-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-01-24", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-01-24", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-06-15", "studyFirstSubmitQcDate": "2016-06-23", "studyFirstPostDateStruct": {"date": "2016-06-28", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-12-12", "resultsFirstSubmitQcDate": "2018-01-31", "resultsFirstPostDateStruct": {"date": "2018-03-01", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-10-23", "lastUpdatePostDateStruct": {"date": "2018-10-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal influenza virus vaccination", "detailedDescription": "This study is designed to investigate the potential effect of benralizumab on the antibody response to the seasonal influenza virus vaccine in patients 12-21 years of age with asthma. Benralizumab will be given subcutaneously (SC) at Weeks 0, 4, and 8 weeks, at which time benralizumab levels will reach steady state. Patients will then receive 1 dose of intramuscular (IM) seasonal influenza virus vaccine at Week 8 and samples drawn at Week 8 and Week 12 to measure the antibody response to the influenza virus"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Male and female adolescent patients", "severe asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "SUPPORTIVE_CARE", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 103, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Benralizumab", "type": "EXPERIMENTAL", "description": "1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.", "interventionNames": ["Drug: Benralizumab", "Drug: Seasonal influenza virus vaccine"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.", "interventionNames": ["Drug: Benralizumab Placebo", "Drug: Seasonal influenza virus vaccine"]}], "interventions": [{"type": "DRUG", "name": "Benralizumab", "description": "Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).", "armGroupLabels": ["Benralizumab"]}, {"type": "DRUG", "name": "Benralizumab Placebo", "description": "Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Seasonal influenza virus vaccine", "description": "Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.", "armGroupLabels": ["Benralizumab", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12", "description": "To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \\[log(z) x\\]), where \"x\" is the postdose HAI antibody titer fold rise from Week 8 and \"z\" is the natural logarithm.", "timeFrame": "4 weeks"}, {"measure": "Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12", "description": "To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "timeFrame": "12 weeks"}, {"measure": "Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a \u22654-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u22654-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "timeFrame": "4 weeks"}, {"measure": "Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer \u226540 at Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u226540-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "timeFrame": "12 weeks"}], "secondaryOutcomes": [{"measure": "Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre \u2265320 at Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u2265320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "timeFrame": "12 weeks"}, {"measure": "Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12", "description": "To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \\[log(z) x\\]), where \"x\" is the postdose microneutralization antibody titer fold rise from Week 8 and \"z\" is the natural logarithm.", "timeFrame": "4 weeks"}, {"measure": "Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12", "description": "To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "timeFrame": "12 weeks"}, {"measure": "Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a \u22654-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u22654-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "timeFrame": "4 weeks"}, {"measure": "Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12", "description": "To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting \u03b22 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of \u22640.75 indicate well-controlled asthma, scores between 0.75 and \u22641.5 indicate partly controlled asthma, and a score \\>1.5 indicates not well controlled asthma", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Female and male patients aged 12 to 21 years, inclusive, at the time of Visit 1\n* Weight of \u226540 kg\n* Documented history of current treatment with Inhaled corticosteroids (ICS) and long-acting \u03b22 agonists (LABA)\n* Morning pre-bronchodilator forced expiratory volume in 1 second (FEV1) of \\>50% predicted at Visit 1 or Visit 2.\n* Airway reversibility (FEV1 \\>12% and 200 ml) demonstrated at Visit 1 or Visit 2 using the Maximum Post-bronchodilator Procedure OR\n* Airway reversibility documented in the previous 12 months prior to Visit 1\n* An exacerbation, 1 or more, that required oral corticosteroids in the previous year OR\n* Any condition assessed by patient recall over the previous 2-4 weeks\n\nExclusion Criteria:\n\n* Clinically important pulmonary disease other than asthma\n* Known history of allergy or reaction to the Investigational Product formulation or influenza vaccine\n* Receipt of an influenza vaccine within 90 days prior to randomization\n* Poorly controlled asthma during the screening period that requires treatment with oral corticosteroids or a hospitalization/emergency room visit for the treatment of asthma\n* Acute illness or evidence of significant active infection or known influenza infection during the current flu season", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "maximumAge": "21 Years", "stdAges": ["CHILD", "ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pamela L Zeitlin, M.D. Ph.D.", "affiliation": "Johns Hopkins University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Research Site", "city": "Mesa", "state": "Arizona", "zip": "85206", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"facility": "Research Site", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Research Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Research Site", "city": "Aurora", "state": "Colorado", "zip": "80012-4016", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Research Site", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Research Site", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Research Site", "city": "Aventura", "state": "Florida", "zip": "33180", "country": "United States", "geoPoint": {"lat": 25.95648, "lon": -80.13921}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33135", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Research Site", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Research Site", "city": "Northfield", "state": "New Jersey", "zip": "08225", "country": "United States", "geoPoint": {"lat": 39.37039, "lon": -74.55015}}, {"facility": "Research Site", "city": "Edmond", "state": "Oklahoma", "zip": "73034", "country": "United States", "geoPoint": {"lat": 35.65283, "lon": -97.4781}}, {"facility": "Research Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "North Charleston", "state": "South Carolina", "zip": "29420", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Research Site", "city": "Arlington", "state": "Texas", "zip": "76018", "country": "United States", "geoPoint": {"lat": 32.73569, "lon": -97.10807}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78221", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Research Site", "city": "Clinton", "state": "Utah", "zip": "84015", "country": "United States", "geoPoint": {"lat": 41.13967, "lon": -112.0505}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "CSP redacted", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3366&filename=d3250c00033-clinical-study-protocol_Redacted.pdf"}, {"label": "Statistical Analysis Plan (SAP)", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3366&filename=d3250C00033-sap-edition-2_redacted.pdf"}, {"label": "ALIZE_redacted_protocol.pdf", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3366&filename=ALIZE_redacted_protocol.pdf"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study duration was up to 23 weeks, consisting of an initial screening period lasting up to 3 weeks, a 12-week treatment period, and a follow-up visit 8 weeks after the last dose of study drug", "recruitmentDetails": "This study was conducted at 30 study centers in the United States between 01 July 2016 and 24 January 2017", "groups": [{"id": "FG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "FG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}, {"groupId": "FG001", "numSubjects": "52"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}, {"groupId": "FG001", "numSubjects": "49"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "BG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "52"}, {"groupId": "BG002", "value": "103"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "16.0", "spread": "2.65", "lowerLimit": "12", "upperLimit": "21"}, {"groupId": "BG001", "value": "15.7", "spread": "2.99", "lowerLimit": "12", "upperLimit": "21"}, {"groupId": "BG002", "value": "15.9", "spread": "2.82", "lowerLimit": "12", "upperLimit": "21"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "\u226512 to \u226417", "categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "72"}]}]}, {"title": "\u226518 to \u226421", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Sex/Gender, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "21"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "42"}]}]}, {"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "61"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "American Indian Or Alaska Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Black Or African American", "categories": [{"measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "26"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "74"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Postdose Strain-specific Hemagglutination-inhibition (HAI) Antibody Geometric Mean Fold Rise From Week 8 to Week 12", "description": "To compare the geometric mean fold rises in influenza strain-specific hemagglutination-inhibition responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \\[log(z) x\\]), where \"x\" is the postdose HAI antibody titer fold rise from Week 8 and \"z\" is the natural logarithm.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received \u22651 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or microneutralization antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Fold change", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.60", "spread": "1.22"}, {"groupId": "OG001", "value": "3.13", "spread": "1.22"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.25", "spread": "1.18"}, {"groupId": "OG001", "value": "3.85", "spread": "1.18"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.42", "spread": "1.16"}, {"groupId": "OG001", "value": "3.17", "spread": "1.16"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.08", "spread": "1.19"}, {"groupId": "OG001", "value": "3.27", "spread": "1.19"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza A H1N1", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "0.87", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.56", "ciUpperLimit": "1.35"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza A H3N2", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "1.19", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.82", "ciUpperLimit": "1.71"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza B Yamagata lineage", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "0.93", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.67", "ciUpperLimit": "1.29"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza B Victoria lineage", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "0.80", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.54", "ciUpperLimit": "1.19"}]}, {"type": "PRIMARY", "title": "Postdose Strain-specific Hemagglutination-inhibition Antibody Geometric Mean Titers Obtained at Week 12", "description": "To compare the geometric mean titers of hemagglutination-inhibition antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Antibody titer", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "521.06", "spread": "1.13"}, {"groupId": "OG001", "value": "518.60", "spread": "1.13"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "170.73", "spread": "1.15"}, {"groupId": "OG001", "value": "219.35", "spread": "1.15"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "61.47", "spread": "1.13"}, {"groupId": "OG001", "value": "63.15", "spread": "1.13"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "53.10", "spread": "1.14"}, {"groupId": "OG001", "value": "66.85", "spread": "1.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza A H1N1", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "1.00", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.76", "ciUpperLimit": "1.31"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza A H3N2", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "1.28", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.93", "ciUpperLimit": "1.77"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza B Yamagata lineage", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "1.03", "ciPctValue": "90", "ciLowerLimit": "0.79", "ciUpperLimit": "1.34"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Influenza B Victoria lineage", "nonInferiorityType": "OTHER", "statisticalMethod": "ANCOVA", "statisticalComment": "The linear model effects are treatment group as a fixed effect and age group (adolescents and young adults) as fixed categorical covariate.", "paramType": "Geometric least-square mean ratio", "paramValue": "1.26", "ciPctValue": "90", "ciLowerLimit": "0.93", "ciUpperLimit": "1.70"}]}, {"type": "PRIMARY", "title": "Proportion of Patients Who Experienced a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a \u22654-fold Rise in Hemagglutination-inhibition Antibody Titer From Week 8 to Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u22654-fold rises in hemagglutination-inhibition antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Proportion of Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.440", "lowerLimit": "0.32", "upperLimit": "0.57"}, {"groupId": "OG001", "value": "0.306", "lowerLimit": "0.20", "upperLimit": "0.43"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.500", "lowerLimit": "0.38", "upperLimit": "0.62"}, {"groupId": "OG001", "value": "0.490", "lowerLimit": "0.37", "upperLimit": "0.62"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.480", "lowerLimit": "0.36", "upperLimit": "0.60"}, {"groupId": "OG001", "value": "0.490", "lowerLimit": "0.37", "upperLimit": "0.62"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.560", "lowerLimit": "0.43", "upperLimit": "0.68"}, {"groupId": "OG001", "value": "0.408", "lowerLimit": "0.29", "upperLimit": "0.54"}]}]}]}, {"type": "PRIMARY", "title": "Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination-inhibition Antibody Titer \u226540 at Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u226540-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Proportion of Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.00", "spread": "251.9", "lowerLimit": "0.94", "upperLimit": "1.00"}, {"groupId": "OG001", "value": "1.00", "spread": "191.3", "lowerLimit": "0.94", "upperLimit": "1.00"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.980", "spread": "136.2", "lowerLimit": "0.91", "upperLimit": "1.00"}, {"groupId": "OG001", "value": "0.980", "spread": "168.6", "lowerLimit": "0.91", "upperLimit": "1.00"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.860", "spread": "144.9", "lowerLimit": "0.75", "upperLimit": "0.93"}, {"groupId": "OG001", "value": "0.796", "spread": "115.0", "lowerLimit": "0.68", "upperLimit": "0.88"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.780", "spread": "178.7", "lowerLimit": "0.66", "upperLimit": "0.87"}, {"groupId": "OG001", "value": "0.878", "spread": "162.2", "lowerLimit": "0.77", "upperLimit": "0.95"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Patients Who Achieved a Strain-specific Postdose Hemagglutination Inhibition Antibody Titre \u2265320 at Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u2265320-fold rises in hemagglutination-inhibition antibody titer at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Proportion of Participants", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.840", "lowerLimit": "0.73", "upperLimit": "0.92"}, {"groupId": "OG001", "value": "0.857", "lowerLimit": "0.75", "upperLimit": "0.93"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.500", "lowerLimit": "0.38", "upperLimit": "0.62"}, {"groupId": "OG001", "value": "0.612", "lowerLimit": "0.48", "upperLimit": "0.73"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.020", "lowerLimit": "0.00", "upperLimit": "0.09"}, {"groupId": "OG001", "value": "0.020", "lowerLimit": "0.00", "upperLimit": "0.09"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.080", "lowerLimit": "0.03", "upperLimit": "0.17"}, {"groupId": "OG001", "value": "0.041", "lowerLimit": "0.01", "upperLimit": "0.12"}]}]}]}, {"type": "SECONDARY", "title": "Postdose Strain-specific Microneutralization Antibody Geometric Mean Fold Rise From Week 8 to Week 12", "description": "To compare the geometric mean fold rises in influenza strain-specific microneutralization antibody responses from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo. Geometric mean fold rise was defined as antilog(z) (mean \\[log(z) x\\]), where \"x\" is the postdose microneutralization antibody titer fold rise from Week 8 and \"z\" is the natural logarithm.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Fold change", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.1", "spread": "521.4"}, {"groupId": "OG001", "value": "4.4", "spread": "329.4"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "149.8"}, {"groupId": "OG001", "value": "3.6", "spread": "210.0"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "148.9"}, {"groupId": "OG001", "value": "3.2", "spread": "141.3"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8", "spread": "224.1"}, {"groupId": "OG001", "value": "3.5", "spread": "195.3"}]}]}]}, {"type": "SECONDARY", "title": "Postdose Strain-specific Serum Microneutralization Antibody Geometric Mean Titers Obtained at Week 12", "description": "To compare the geometric mean titers of microneutralization antibody as a measure of influenza strain-specific response at Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "Antibody titer", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "3774.1", "spread": "181.7"}, {"groupId": "OG001", "value": "3969.1", "spread": "154.0"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "4307.5", "spread": "169.0"}, {"groupId": "OG001", "value": "4351.3", "spread": "171.0"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "350.2", "spread": "103.6"}, {"groupId": "OG001", "value": "336.2", "spread": "114.3"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "164.5", "spread": "178.5"}, {"groupId": "OG001", "value": "234.4", "spread": "135.0"}]}]}]}, {"type": "SECONDARY", "title": "Proportion of Patients Who Experience a Strain-specific Postdose Antibody Response at Week 12 With Antibody Response Defined as a \u22654-fold Rise in Microneutralization Antibody Titer From Week 8 to Week 12", "description": "To compare the proportions of patients experiencing influenza strain-specific responses as measured by \u22654-fold rises in microneutralization antibody titer from Week 8 to Week 12 between patients receiving benralizumab 30mg and patients receiving placebo.", "populationDescription": "The vaccine immunogenicity analysis set included all randomized patients who received at least 1 dose of planned study drugs, had pre- (Week 8) and postdose (Week 12) HAI or MN antibody measurements, and had no protocol deviations judged to have the potential to interfere with the generation or interpretation of an antibody response.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "90% Confidence Interval", "unitOfMeasure": "Proportion of Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"title": "Influenza A H1N1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.420", "spread": "251.9", "lowerLimit": "0.30", "upperLimit": "0.55"}, {"groupId": "OG001", "value": "0.408", "spread": "191.3", "lowerLimit": "0.29", "upperLimit": "0.54"}]}]}, {"title": "Influenza A H3N2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.440", "spread": "136.2", "lowerLimit": "0.32", "upperLimit": "0.57"}, {"groupId": "OG001", "value": "0.429", "spread": "168.6", "lowerLimit": "0.31", "upperLimit": "0.56"}]}]}, {"title": "Influenza B Yamagata lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.280", "spread": "144.9", "lowerLimit": "0.18", "upperLimit": "0.40"}, {"groupId": "OG001", "value": "0.388", "spread": "115.0", "lowerLimit": "0.27", "upperLimit": "0.52"}]}]}, {"title": "Influenza B Victoria lineage", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.400", "spread": "178.7", "lowerLimit": "0.28", "upperLimit": "0.53"}, {"groupId": "OG001", "value": "0.388", "spread": "162.2", "lowerLimit": "0.27", "upperLimit": "0.52"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Asthma Control Questionnaire 6 (ACQ-6) Score at Week 12", "description": "To compare the change from baseline at Week 12 in mean ACQ-6 score between patients receiving benralizumab 30mg and patients receiving placebo. The ACQ-6 assesses asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short-acting \u03b22 agonist use). Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled). The mean ACQ-6 score is the mean of the responses to each question. Mean scores of \u22640.75 indicate well-controlled asthma, scores between 0.75 and \u22641.5 indicate partly controlled asthma, and a score \\>1.5 indicates not well controlled asthma", "populationDescription": "The full analysis set included all patients who were randomized and received any investigational product.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Full Range", "unitOfMeasure": "Score on a scale", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous"}, {"id": "OG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "50"}, {"groupId": "OG001", "value": "49"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.50", "lowerLimit": "-2.8", "upperLimit": "4.3"}, {"groupId": "OG001", "value": "-0.42", "lowerLimit": "-2.7", "upperLimit": "1.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "All AEs, including SAEs, were collected from the time the patient, parent, or legal guardian signed the informed consent/assent throughout the treatment period and including the follow-up period (through Week 20).", "eventGroups": [{"id": "EG000", "title": "Benralizumab 30mg", "description": "Benralizumab 30mg/day subcutaneous", "deathsNumAffected": 0, "deathsNumAtRisk": 51, "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 28, "otherNumAtRisk": 51}, {"id": "EG001", "title": "Placebo", "description": "Placebo to benralizumab subcutaneous", "deathsNumAffected": 0, "deathsNumAtRisk": 52, "seriousNumAffected": 2, "seriousNumAtRisk": 52, "otherNumAffected": 23, "otherNumAtRisk": 52}], "seriousEvents": [{"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}], "otherEvents": [{"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 52}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 52}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 52}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Ligament sprain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 52}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 52}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 52}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 52}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 52}]}, {"term": "Acne", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 19.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 51}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 52}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "At least 30 days prior to submission for publication/presentation, Institution and PI shall jointly provide AZ with material for review. No publication/presentation may include any of AZ's Confidential Information without AZ's written approval. AZ can request Institution and PI to withhold material from submission for publication/presentation for an additional 90 days to allow AZ to establish and preserve its proprietary rights in the material being submitted for publication/presentation."}, "pointOfContact": {"title": "Mitchell Goldman MD, PhD", "organization": "AstraZeneca", "email": "Mitchell.Goldman@astrazeneca.com", "phone": "+1 610 457 5585"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2015-12-14", "uploadDate": "2017-12-12T05:06", "filename": "Prot_000.pdf", "size": 1965218}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-03-06", "uploadDate": "2017-12-12T05:16", "filename": "SAP_001.pdf", "size": 1270062}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10295", "name": "Influenza, Human", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC01", "name": "Infections"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000571386", "term": "Benralizumab"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M287399", "name": "Benralizumab", "asFound": "Aorta", "relevance": "HIGH"}, {"id": "M17360", "name": "Vaccines", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}